YOUR SUPPORT ENABLES US TO TURN RESEARCH BREAKTHROUGHS INTO LIFESAVING TREATMENTS
This year, we ask you to lend your support for our research in precision medicine and targeted treatment approaches.
Our talented team of scientists and clinicians is deciphering the molecular genetics of each patient’s disease and developing novel strategies for personalized therapies. With an unsurpassed repository of clinical and research data and dedicated bioinformaticians, we are uniquely positioned to conduct in-depth analyses on very large data sets, which in turn drive innovation in clinical applications. In addition, our collaborations with other international centers enhance our data by maximizing the scope of population variance.
Genomic discovery across medical fields is progressing at an ever-increasing rate. We are especially excited to propel this discovery in myeloma and related diseases.
Sixty percent of our research funding comes from philanthropy. It is your support that enables us to turn research breakthroughs into lifesaving treatments for patients around the world. Every gift, no matter the size, advances the reality of cure.
Thank you for making a difference.
A remittance envelope is enclosed for your convenience. Or, you can donate online at http://myeloma.uams.edu/giving/.
Expanding Molecular Genetics Expertise
Brian Walker, Ph.D., professor and director of research at the Myeloma Institute since October 2015, heads up a team that is integrating gene expression profiling with DNA molecular profiling as a means of developing personalized treatments. Once a postdoctoral fellow himself, Walker has brought on board two new, talented Ph.D.s to help drive forward the research.
Samrat Roy Choudhury, Ph.D., came to the Myeloma Institute from Purdue University in Indiana, where he was a postdoctoral research assistant with the Department of Agricultural and Biological Engineering. His focus there was on epigenetic biomarkers in cancer cells and epigenomic toxicity of chemical compounds and engineered nanomaterials. Roy Choudhury received his Ph.D. in biotechnology and a master’s degree in zoology with cytogenetics and molecular biology, both from the University of Calcutta.
Aneta Mikulasova, Ph.D., joined the Myeloma Institute from Masaryk University in the Czech Republic with a background in molecular biology and genetics. The thesis topic of her recently earned doctoral degree was the prognostic value of genetic abnormalities in monoclonal gammopathy of undetermined significance (MGUS).